Total for the last 12 months
number of access : ?
number of downloads : ?
ID 118977
Author
Yamashita, H Kanaiso Hospital
Bando, Hiroshi Kanaiso Hospital|Tokushima University|Medical Research|Japan Low Carbohydrate Diet Promotion Association KAKEN Search Researchers
Kato, Y Kanaiso Hospital
Ogura, K Kanaiso Hospital
Kato, Y Kanaiso Hospital
Kawata, T Kanaiso Hospital
Keywords
Oral semaglutide (Rybelsus)
Gastrointestinal adverse events (GIAEs)
Semaglutide Treatment Effect in People with Obesity (STEP)
Glucagon-Like Peptide 1 receptor agonist (GLP-1RA)
Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
Content Type
Journal Article
Description
Background: Recent topic for diabetes includes oral semaglutide (Rybelsus).
Case presentation: A Patient is 75-year-old female with Type 2 diabetes (T2D). Her HbA1c has been 6.8-7.6% for long, but increased to 8.4-8.8% in Jan 2022 with BMI 27.6 kg/m2.
Results: She started Rybelsus 3-7mg/day, and then weight and HbA1c decreased as 7kg and 1.6% in 4 months.
Discussion: Rybelsus is known for improvement of weight and glucose variability. For her clinical effects, some probable reasons include ‘70s for age, less developed microangiopathy and macroangiopathy, longer fasting time period after Rybelsus intake. This case will become useful reference for diabetic research.
Journal Title
SunText Review of Case Reports & Images
ISSN
27664589
Publisher
SunText Reviews
Volume
3
Issue
2
Start Page
147
Published Date
2022-06-27
Rights
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences